Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients
Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
This prospective, randomized, double blinded study is intended to enroll a total of 92
patients undergoing thoracic surgery with general endotracheal anesthesia at Parkland
Hospital. Patients will be randomized to receive either neostigmine or sugammadex for
reversal of neuromuscular blockade. Merck, Inc. will supply the sugammadex through an
agreement with Parkland Investigational Drug Services. Neostigmine is readily available for
anesthesiologists to use and is the current standard of care for reversal of neuromuscular
blockade. A standardized anesthetic protocol that is usual and customary for the type of
operation the patient is having will be provided to the anesthesia teams of enrolled
subjects. The remainder of the anesthetic care of the subject will not deviate from the
standard of care. The surgeon, anesthesia team, postoperative recovery nurse, and research
assistant will be blinded as to which reversal drug the patient receives. The only individual
that will know to which drug the patient has been randomized will be the pharmacist who draws
up the medication(s). A blinded research assistant will record postoperative outcomes and the
patient will be followed 90 minutes postoperatively for any adverse events.